Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Lymphocytic Leukemia

Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping

Leukemia volume 21, pages 2442–2451 (2007)Cite this article

Abstract

In CLL data from chromosome banding analysis (CBA) have been scarce due to the low proliferative activity of CLL cells in vitro. We improved the cultivation technique using an immunostimulatory CpG-oligonucleotide DSP30 and IL-2. A total of 506 CLL samples were analysed with CBA and interphase FISH using probes for the detection of trisomy 12, IgH rearrangements and deletions of 6q21, 11q22.3 (ATM), 13q14 (D13S25 and D13S319) and 17p13 (TP53). A total of 500 of 506 (98.8%) cases were successfully stimulated for metaphase generation and are subject to this study. Aberrations were detected in 415 of 500 (83.0%) cases by CBA and in 392 of 500 (78.4%) cases by FISH. CBA detected 832 abnormalities and FISH only 502. Therefore, CBA offers important information in addition to FISH. (1) CLL is characterized mainly by genomic imbalances and reciprocal translocations are rare. (2) A subgroup with complex aberrant karyotype (16.4%) is identified which is associated with an unmutated IgVH status and CD38 expression (P=0.034 and 0.02, respectively). (3) Additional abnormalities are detectable providing new biological insights into different CLL subclasses revealing a much more heterogeneous pattern of cytogenetic abnormalities as assumed so far based on FISH data only. Therefore, prospective clinical trials should evaluate the prognostic impact of newly available CBA data.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Shanafelt TD, Geyer SM, Kay NE . Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202–1210.

    Article  CAS  PubMed  Google Scholar 

  2. Kay NE, O’brien SM, Pettitt AR, Stilgenbauer S . The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia. Leukemia 2007, Leukemia (2007) 21, –;, 14 June 2007.

  3. Gahrton G, Robert KH, Friberg K, Zech L, Bird AG . Nonrandom chromosomal aberrations in chronic lymphocytic leukemia revealed by polyclonal B-cell-mitogen stimulation. Blood 1980; 56: 640–647.

    CAS  PubMed  Google Scholar 

  4. Juliusson G, Oscier DG, Fitchett M, Ross FM, Stockdill G, Mackie MJ et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–724.

    Article  CAS  PubMed  Google Scholar 

  5. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184.

    CAS  PubMed  Google Scholar 

  6. Bentz M, Huck K, du MS, Joos S, Werner CA, Fischer K et al. Comparative genomic hybridization in chronic B-cell leukemias shows a high incidence of chromosomal gains and losses. Blood 1995; 85: 3610–3618.

    CAS  PubMed  Google Scholar 

  7. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  PubMed  Google Scholar 

  8. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799–804.

    Article  CAS  PubMed  Google Scholar 

  9. Buhmann R, Kurzeder C, Rehklau J, Westhaus D, Bursch S, Hiddemann W et al. CD40L stimulation enhances the ability of conventional metaphase cytogenetics to detect chromosome aberrations in B-cell chronic lymphocytic leukaemia cells. Br J Haematol 2002; 118: 968–975.

    Article  CAS  PubMed  Google Scholar 

  10. Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002; 16: 327–334.

    Article  CAS  PubMed  Google Scholar 

  11. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C . Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108: 3152–3160.

    Article  CAS  PubMed  Google Scholar 

  12. Matutes E, Owusu-Ankomah K, Morilla R, Garcia MJ, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640–1645.

    CAS  PubMed  Google Scholar 

  13. Moreau EJ, Matutes E, A’Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997; 108: 378–382.

    Article  CAS  PubMed  Google Scholar 

  14. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002; 35: 20–29.

    Article  PubMed  Google Scholar 

  15. ISCN In: Mitelman F (eds). ISCN 1995, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. S Karger: Basel, 1995, pp 1–110.

  16. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59.

    Article  CAS  PubMed  Google Scholar 

  17. Kern W, Haferlach T, Schnittger S, Schoch C . Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia. Arch Pathol Lab Med 2005; 129: 410–411.

    PubMed  Google Scholar 

  18. Hiller B, Bradtke J, Balz H, Rieder H . CyDAS: a cytogenetic data analysis system. Bioinformatics 2005; 21: 1282–1283.

    Article  CAS  PubMed  Google Scholar 

  19. Haferlach C, Rieder H, Lillington DM, Dastugue N, Hagemeijer A, Harbott J et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007; 46: 494–499.

    Article  CAS  PubMed  Google Scholar 

  20. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    CAS  PubMed  Google Scholar 

  21. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.

    Article  CAS  PubMed  Google Scholar 

  22. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111.

    Article  CAS  PubMed  Google Scholar 

  23. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951.

    Article  CAS  PubMed  Google Scholar 

  24. Reddy KS . Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006; 132: 705–722.

    Article  CAS  PubMed  Google Scholar 

  25. Stilgenbauer S, Dohner K, Bentz M, Lichter P, Dohner H . Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 1998; 76: 101–110.

    Article  CAS  PubMed  Google Scholar 

  26. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742–751.

    Article  CAS  PubMed  Google Scholar 

  27. Van Den Neste E, Robin V, Francart J, Hagemeijer A, Stul M, Vandenberghe P et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia 2007; 21: 1715–1722.

    Article  CAS  PubMed  Google Scholar 

  28. Stilgenbauer S, Bullinger L, Lichter P, Dohner H . Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993–1007.

    Article  CAS  PubMed  Google Scholar 

  29. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O’Fallon JR, Allmer C et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287–295.

    Article  PubMed  Google Scholar 

  30. Chen YH, Peterson LC, Dittmann D, Evens A, Rosen S, Khoong A et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol 2007; 127: 182–191.

    Article  CAS  PubMed  Google Scholar 

  31. Shankey TV, Forman M, Scibelli P, Cobb J, Smith CM, Mills R et al. An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70: 259–269.

    Article  PubMed  Google Scholar 

  32. Kern W, Dicker F, Schnittger S, Schoch C, Haferlach T . Correlation of flow cytometrically determined expression of ZAP-70 using two different antibodies with IgVH mutation status and cytogenetics in patients with chronic lymphocytic leukemia. Blood 2006; 108: 150a (Abstract 495).

    Google Scholar 

  33. Juliusson G, Robert KH, Ost A, Friberg K, Biberfeld P, Nilsson B et al. Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma. Blood 1985; 65: 134–141.

    CAS  PubMed  Google Scholar 

  34. Juliusson G . Immunologic and cytogenetic studies improve prognosis prediction in chronic B-lymphocytic leukemia. A multivariate analysis of 24 variables. Cancer 1986; 58: 688–693.

    Article  CAS  PubMed  Google Scholar 

  35. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  36. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T . The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004; 89: 1082–1090.

    PubMed  Google Scholar 

  37. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T . Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005; 43: 227–238.

    Article  CAS  PubMed  Google Scholar 

  38. Sole F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168–1178.

    CAS  PubMed  Google Scholar 

  39. Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007; 109: 1202–1210.

    Article  CAS  PubMed  Google Scholar 

  40. Cuneo A, Bigoni R, Negrini M, Bullrich F, Veronese ML, Roberti MG et al. Cytogenetic and interphase cytogenetic characterization of atypical chronic lymphocytic leukemia carrying BCL1 translocation. Cancer Res 1997; 57: 1144–1150.

    CAS  PubMed  Google Scholar 

  41. Sen F, Lai R, Albitar M . Chronic lymphocytic leukemia with t(14;18) and trisomy 12. Arch Pathol Lab Med 2002; 126: 1543–1546.

    PubMed  Google Scholar 

  42. Crossen PE . Genes and chromosomes in chronic B-cell leukemia. Cancer Genet Cytogenet 1997; 94: 44–51.

    Article  CAS  PubMed  Google Scholar 

  43. Dyer MJ, Zani VJ, Lu WZ, O’Byrne A, Mould S, Chapman R et al. BCL2 translocations in leukemias of mature B cells. Blood 1994; 83: 3682–3688.

    CAS  PubMed  Google Scholar 

  44. Vizcarra E, Martinez-Climent JA, Benet I, Marugan I, Terol MJ, Prosper F et al. Identification of two subgroups of mantle cell leukemia with distinct clinical and biological features. Hematol J 2001; 2: 234–241.

    Article  CAS  PubMed  Google Scholar 

  45. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937–3949.

    Article  CAS  PubMed  Google Scholar 

  46. Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res 2003; 63: 36–38.

    CAS  PubMed  Google Scholar 

  47. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437–443.

    Article  CAS  PubMed  Google Scholar 

  48. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278–3281.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all clinicians for sending CLL samples to our laboratory for diagnostic purposes.

Author information

Authors and Affiliations

  1. MLL Munich Leukemia Laboratory, Munich, Germany

    C Haferlach, F Dicker, S Schnittger, W Kern & T Haferlach

Authors
  1. C Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Dicker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Schnittger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Haferlach.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haferlach, C., Dicker, F., Schnittger, S. et al. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia 21, 2442–2451 (2007). https://doi.org/10.1038/sj.leu.2404935

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404935

Keywords

This article is cited by

Search

Advanced search

Quick links